DNER and B-cell non-Hodgkin lymphoma: To this end, the therapeutic utility of BET inhibitors has been proven in several hematopoietic diseases, including B-cell lymphoma [22, 34, 35] and acute lymphoblastic leukemia [36–39], however to our knowledge their value in PTCL has not been investigated.